The FDA last week approved a combination of...

...Roche drugs, Tecentriq and Avastin, as a frontline therapy for hepatocellular carcinoma, the most common form of liver cancer. The Roche combo will be the first major competitor to Bayer's Nexavar since its 2007 approval. Nexavar currently holds preferred status under the pharmacy benefit for 9% of all covered lives, growing to 42% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 6/1/20